AstraZeneca

5 September 2022 08:06

Forxiga approved in China for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes

AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in China to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death and hospitalisation for heart failure (hHF) in adults with chronic kidney disease (CKD) at risk of progression with and without type-2 diabetes (T2D).

11 Juni 2020 08:01

AstraZeneca to showcase leadership in treating type-2 diabetes and cardiorenal complications at ADA 2020

AstraZeneca will present new data from the landmark Phase III DAPA-HF and DECLARE-TIMI 58 trials at the upcoming 80th American Diabetes Association (ADA) Virtual Scientific Sessions, 12-16 June 2020. The data are among 23 accepted abstracts.....

28 Mars 2020 14:20

Farxiga reduced the incidence of heart failure worsening or cardiovascular death in a sub-analysis from landmark Phase III DAPA-HF trial

New data from a sub-analysis of the landmark Phase III DAPA-HF trial showed that AstraZeneca’s Farxiga (dapagliflozin) reduced the incidence of the primary composite endpoint of heart failure (HF) worsening or cardiovascular (CV) death compared to placebo, in patients with heart failure with reduced ejection fraction (HFrEF), irrespective of their background therapy.

15 November 2019 08:02

Qtrilmet approved in the EU for the treatment of type-2 diabetes

AstraZeneca today announced that the European Commission (EC) has approved Qtrilmet (metformin hydrochloride, saxagliptin and dapagliflozin) modified-release tablets to improve glycaemic control in adults with type-2 diabetes (T2D).

7 November 2019 22:41

Roxadustat significantly increased haemoglobin levels for chronic kidney disease patients with anaemia in Phase III OLYMPUS and ROCKIES trials

AstraZeneca today presented detailed results from the Phase III OLYMPUS and ROCKIES trials showing that roxadustat significantly increased haemoglobin (Hb) levels in non-dialysis-dependent (NDD) and dialysis-dependent (DD) patients with anaemia from chronic kidney disease (CKD), respectively.

21 Oktober 2019 08:02

Farxiga approved in the US to reduce the risk of hospitalisation for heart failure in patients with type-2 diabetes

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure (hHF) in adults with type-2 diabetes (T2D) and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors.

4 Oktober 2019 08:02

Fasenra approved in the US for self-administration in a new pre-filled auto-injector, the Fasenra Pen

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved the self-administration of Fasenra (benralizumab) in a pre-filled, single-use auto-injector (the Fasenra Pen).

23 September 2019 08:02

Qtrilmet recommended for approval in EU by CHMP for the treatment of type-2 diabetes

AstraZeneca today announced that Qtrilmet (metformin hydrochloride, saxagliptin and dapagliflozin) modified-release tablets have been recommended for marketing authorisation in the European Union for the treatment of adults with type-2 diabetes (T2D).

16 September 2019 08:09

FDA grants Fast Track designation for Farxiga in heart failure

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to reduce the risk of cardiovascular (CV) death, or the worsening of heart failure, in adults with heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF).

1 September 2019 14:33

Detailed results from Phase III DAPA-HF trial showed Farxiga significantly reduced both the incidence of cardiovascular death and the worsening of heart failure

AstraZeneca today announced detailed results from the landmark Phase III DAPA-HF trial that showed Farxiga (dapagliflozin) on top of standard of care reduced both the incidence of cardiovascular death and the worsening of heart failure.

20 Augusti 2019 08:02

Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure

AstraZeneca today announced positive results from the landmark Phase III DAPA-HF trial which showed that Farxiga(dapagliflozin) met theprimary composite endpoint with a statistically-significant and clinically-meaningful reduction of cardiovascular death or the worsening of heart failure (defined as hospitalisation or an urgent heart failure visit), compared to placebo.

5 Augusti 2019 08:04

Forxiga label updated in the EU in type-2 diabetes

AstraZeneca today announced that the European Commission has approved an update to the marketing authorisation for Forxiga (dapagliflozin) to include positive cardiovascular (CV) outcomes and renal data from the Phase III DECLARE-TIMI 58 trial in adults with type-2 diabetes (T2D). The trial enrolled a majority of patients with no existing cardiovascular disease.

Nyhetsarkiv